VIA
IGC icon

Vident Investment Advisory’s IGC Pharma IGC Stock Holding History

Vident Investment Advisory’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-121,563
Closed -$52K – 1251
2022
Q3 		$52K Buy
121,563
+13,132
+12% +$7K ﹤0.01% 1098
2022
Q2 		$57K Buy
108,431
+4,420
+4% +$2.79K ﹤0.01% 1234
2022
Q1 		$99K Buy
104,011
+41,457
+66% +$40.3K ﹤0.01% 1231
2021
Q4 		$61K Buy
62,554
+6,224
+11% +$8.35K ﹤0.01% 1196
2021
Q3 		$83K Buy
+56,330
New +$91.1K ﹤0.01% 1140

Other funds holding IGC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vident Investment Advisory's IGC Position: Q4 2022 in Review

Vident Investment Advisory sold out of IGC Pharma (IGC) in Q4 2022, closing a stake of 121,563 shares — an estimated $52K sold.

Vident Investment Advisory first reported a position in IGC in Q3 2021 and held it in 5 quarters. The position peaked at $99K in Q1 2022. 26 funds tracked by Wall St. Rank hold IGC as of Q4 2022.

  • Vident Investment Advisory reported no remaining IGC Pharma position as of Q4 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 121,563 IGC Pharma shares in Q4 2022, an estimated $52K.
  • Vident Investment Advisory first reported a position in IGC Pharma in Q3 2021 and held it in 5 quarters.
  • Vident Investment Advisory's IGC Pharma position peaked at $99K in Q1 2022.
  • 26 funds tracked by Wall St. Rank held IGC Pharma as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.